Today: 20 May 2026
Opendoor stock edges up as mortgage rates hover near 3-year lows — what to watch next
22 January 2026
1 min read

Opendoor stock edges up as mortgage rates hover near 3-year lows — what to watch next

New York, Jan 22, 2026, 13:17 EST — Regular session

Shares of Opendoor Technologies Inc edged up roughly 1.7% to $6.59 in Thursday afternoon trading, after hitting an intraday high of $6.78. The stock gained 11 cents on volume of about 25.6 million shares.

The shift brings borrowing costs back into the spotlight for online homebuyers. Opendoor’s “iBuyer” approach means it buys homes outright and flips them, so changes in mortgage rates directly affect demand, pricing flexibility, and inventory carrying expenses.

This is crucial now as rate data shifts in tiny increments, settling at levels investors haven’t encountered recently. For a company reliant on increased transactions without sacrificing margin, even a handful of basis points can shift the outlook.

Wednesday’s Mortgage Bankers Association survey showed the average contract rate on 30-year fixed conforming loans ticked down slightly to 6.16% from 6.18%. Joel Kan, the MBA’s vice president and deputy chief economist, noted this marks the lowest 30-year fixed rate since September 2024. The report also highlighted refinance activity hitting its highest level since September 2025.

Freddie Mac’s latest weekly average for the 30-year fixed mortgage rate inched up to 6.09% from 6.06% the previous week, yet it still hovered near a three-year low, an AP report said. The 10-year Treasury yield, which often influences mortgage rates, was about 4.27% at midday Thursday, climbing from 4.17% a week earlier.

For Opendoor, investors see this mix as a crucial test: can easing financing costs and a slight uptick in buyer demand boost resale margins, or will the market remain hampered by scarce supply and cautious buyers? The company also vies for both attention and customers against traditional agents and online housing platforms, where rate changes can swiftly alter activity.

But the situation works both ways. Should yields continue rising or mortgage rates climb again, demand could drop quickly, pushing resale timelines longer. That leaves home-flippers vulnerable to price drops and steeper carrying costs in a sector already heavy on capital.

Traders are now eyeing the next Freddie Mac mortgage-rate release on Jan. 29 to see if the recent rate drift is gaining real traction.

Stock Market Today

  • Stock Market Today May 20: Nasdaq Rises 1.5% on Renewed Risk Appetite
    May 20, 2026, 5:43 PM EDT. The S&P 500 gained 1.08% to 7,432.97, Nasdaq rose 1.54% to 26,270.36, and Dow advanced 1.31% to 50,009.34 amid falling oil prices and easing Treasury yields. AI hardware stocks like AMD and Super Micro Computer led gains, with Nvidia up 1.3% before its earnings report. Software names Salesforce and CrowdStrike also recovered. Hasbro declined nearly 9% despite beating earnings forecasts due to cautious guidance. Investor optimism reflects hopes for an end to the U.S.-Iran conflict, lowering West Texas Intermediate crude by 5% to $99 a barrel. Nvidia's earnings beat was met with muted reaction as investors awaited stronger sales forecasts. The Motley Fool highlighted other top stock picks, noting Nvidia and Netflix's historic outperformance over the S&P 500.

Latest articles

MicroAlgo Shares Surge 40% as Quantum Release Drives MLGO Spike

MicroAlgo Shares Surge 40% as Quantum Release Drives MLGO Spike

20 May 2026
MicroAlgo shares surged 39.95% to $5.36 after the company announced a quantum image-processing algorithm, with volume reaching 9.74 million shares versus a 447,270 average. The stock hit $6.87 intraday before slipping to $5.22 after hours. No customer deals, revenue targets, or product launch dates were disclosed. Market cap stood near $66.7 million at the close.
Immunovant Stock Surges 35% After Arthritis Drug Data: Why Wall Street Is Repricing IMVT

Immunovant Stock Surges 35% After Arthritis Drug Data: Why Wall Street Is Repricing IMVT

20 May 2026
Immunovant shares jumped 35.3% to $35.56 after reporting 16-week data showing its drug IMVT-1402 produced ACR20, ACR50, and ACR70 response rates of 72.7%, 54.5%, and 35.8% in difficult-to-treat rheumatoid arthritis. Roivant Sciences, its majority owner, rose 14.9%. No new safety signals were reported. The trial enrolled 170 patients, most of whom had failed two prior advanced therapies.
FuelCell Energy surges as AI-fueled rally hits again, analysts wary

FuelCell Energy surges as AI-fueled rally hits again, analysts wary

20 May 2026
FuelCell Energy shares surged 16.5% to $20.22 Wednesday, rebounding after a two-day selloff. The move tracked a 1.5% gain in the Nasdaq Composite and renewed interest in companies supplying power to AI data centers. FuelCell reported a $26.1 million quarterly loss and a declining backlog, despite higher revenue and new data-center proposals. Peers traded mixed, with Bloom Energy up and Plug Power down.
Adobe stock rises as Sundance-linked AI push puts Firefly Foundry back in focus
Previous Story

Adobe stock rises as Sundance-linked AI push puts Firefly Foundry back in focus

Silver price today hits fresh record above $96 as dollar slips and Fed meeting looms
Next Story

Silver price today hits fresh record above $96 as dollar slips and Fed meeting looms

Go toTop